Welcome to our dedicated page for NH news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NH stock.
NantHealth (NH) delivers innovative healthcare solutions through its unique integration of advanced diagnostics and comprehensive data analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in precision medicine.
Access timely reports on clinical developments, technology partnerships, and operational milestones that shape NH's position in healthcare innovation. Our curated collection includes earnings announcements, regulatory filings, product launch details, and strategic collaborations within the medical technology sector.
Key areas of coverage feature NH's systems-based approach to treatment optimization, advancements in biometric data integration, and initiatives supporting value-based care models. Stay informed about developments impacting personalized healthcare delivery and diagnostic technology evolution.
Bookmark this page for streamlined access to verified NH updates. Check regularly for new insights into how the company continues bridging healthcare services with actionable data solutions.
NantHealth, Inc. (NASDAQ: NH) is set to report its third-quarter financial results for 2022 on November 3, 2022, after market close. The company's management will conduct a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the performance details. Investors can join the call by dialing 800-942-2493 (U.S.) or 212-231-2931 (international). The call will also be available online at nanthealth.com.
NantHealth Inc. (NASDAQ: NH) has been awarded full URAC accreditation for Health Utilization Management for its Eviti Connect platform, extending accreditation through September 1, 2025. This certification acknowledges NantHealth's compliance with recognized standards in healthcare quality and management. The URAC accreditation process validates the effectiveness of their processes, enhancing patient outcomes and demonstrating the company's commitment to quality healthcare delivery.
NantHealth reported Q2 2022 net revenue of $16.5 million, a slight increase from $16.1 million in Q2 2021, marking continued growth for the third consecutive quarter. The company maintained a gross margin of 55%. Despite this growth, operating expenses rose, with SG&A increasing to $14 million and R&D expenses reaching $5.9 million. Net loss narrowed to $12.5 million or $0.11 per share, an improvement from $15.3 million or $0.13 per share a year earlier. Cash reserves stood at $5.7 million.
NantHealth, Inc. (NASDAQ: NH) will report its financial results for Q2 2022 on August 4, 2022, post-market. The company specializes in transforming complex data into actionable insights for various sectors, including healthcare and telecommunications. A conference call is scheduled on the same day at 1:30 p.m. PT to discuss the performance.
Interested participants can join by calling 800-771-6692 in the U.S. and Canada or 212-231-2907 internationally. The call will also be streamed live on their website.
The OpenNMS Group, a subsidiary of NantHealth (NASDAQ: NH), announced the release of OpenNMS Horizon 30 and OpenNMS Plugin API 1.0. Horizon 30 introduces enhanced NetFlow capabilities including real-time alarm generation and centralized device configuration backups. Key features also include improved device inventory workflows, OpenAPI support, and an updated Grafana plugin. The Plugin API fosters a stable development ecosystem for building integrations and plugins, ensuring compatibility with future releases. These updates aim to enhance network monitoring and performance for enterprise users.
NantHealth, Inc. (NASDAQ: NH) reported Q1 2022 net revenue of $16.4 million, a slight increase from $16.2 million in Q1 2021. Gross profit remained stable at 56% of total revenue. The company faced rising expenses, with SG&A increasing to $15.0 million from $12.5 million, and R&D expenses rising to $5.7 million. Net loss from continuing operations was $16.0 million or $0.14 per share, compared to a net loss of $15.4 million or $0.14 per share in the previous year. Cash reserves stood at $16.1 million.
NantHealth, Inc. (NASDAQ: NH) will report its 2022 first quarter financial results on May 5, 2022, after market close. Following the announcement, management will conduct a conference call at 1:30 p.m. PT to discuss performance. Interested parties can join via phone or through an online broadcast.
The company specializes in enterprise solutions that convert complex data into actionable insights for industries such as healthcare and telecommunications, offering solutions for real-time coverage decision support and data analysis.
OpenNMS Group, a subsidiary of NantHealth (NASDAQ: NH), has released the OpenNMS Meridian 2022, enhancing security and functionality in its open-source network monitoring platform. Key updates include improved security by enabling non-root user access, faster analytics processing, simplified communication protocols, enhanced geolocation features, and an expanded set of REST APIs for integration. OpenNMS is also focusing on cybersecurity measures, aligning with ISO 27001, and adopting penetration testing in development processes. These updates aim to meet enterprise demands for security and compliance.
NantHealth, a provider of enterprise solutions, announced participation in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:50 p.m. ET. The event will highlight NantHealth's capabilities in transforming complex data into actionable insights for various industries, including healthcare and life sciences. A live audio webcast will be available on NantHealth's corporate website for interested investors. This engagement underscores NantHealth's commitment to innovation in data solutions and security.
